Product news

Share this article:
Genzyme announced an FDA marketing approval for Mozobil (plerixafor injection), a drug to be used in combination with a granulocyte-colony stimulating factor to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. The product also received an orphan drug designation. 
 
Following an FDA safety alert on oral sodium phosphates (OSP), C.B. Fleet has announced a voluntary recall of over-the-counter products Fleet Phospho-soda and Fleet Phospho-soda EZ-Prep Bowel Cleansing System. The FDA recommended that these products not be used for bowel cleansing. Two prescription OSPs manufactured by Salix Pharmaceuticals, Visicol and OsmoPrep, were given box warnings related to the risk of acute kidney injury.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.